ID

18472

Description

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00078260

Link

https://clinicaltrials.gov/show/NCT00078260

Keywords

Versions (2)
  1. 11/6/16 11/6/16 -
  2. 11/7/16 11/7/16 -
Uploaded on

November 7, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non-Small Cell Lung Cancer NCT00078260

English

Eligibility Non-Small Cell Lung Cancer NCT00078260

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of locally advanced or metastatic (stage iii or iv at entry) non-small cell lung cancer (nsclc) that is not amenable to curative therapy.
Description

Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | Disease Curative treatment Amenable | TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C0007131
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [2]
C0278987
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C3900053
UMLS CUI [4]
C3258246
patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
Description

Prior Chemotherapy Platinum-Based Locally Advanced Malignant Neoplasm | Prior Chemotherapy Platinum-Based Metastatic Neoplasm | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Additional Recurrence

Data type

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C1514162
UMLS CUI [1,3]
C0677984
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C1514162
UMLS CUI [2,3]
C2939420
UMLS CUI [3,1]
C0600558
UMLS CUI [3,2]
C0392920
UMLS CUI [4]
C0085533
UMLS CUI [5,1]
C0392920
UMLS CUI [5,2]
C1524062
UMLS CUI [5,3]
C2825055
no more than two prior systemic anti-cancer therapies will be allowed.
Description

cancer treatment Systemic Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C1265611
prior radiation therapy is allowed to less than 25% of the bone marrow. prior radiation to the whole pelvis is not allowed. prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Description

prior radiation therapy Bone Marrow Percentage | prior radiation therapy Whole-Pelvis | prior radiation therapy Completed | Toxic effect Patient Recovered

Data type

boolean

Alias
UMLS CUI [1,1]
C0279134
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0439165
UMLS CUI [2,1]
C0279134
UMLS CUI [2,2]
C3827467
UMLS CUI [3,1]
C0279134
UMLS CUI [3,2]
C0205197
UMLS CUI [4,1]
C0600688
UMLS CUI [4,2]
C0030705
UMLS CUI [4,3]
C0521108
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnancy.
Description

Pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0032961
breast-feeding.
Description

Breast Feeding

Data type

boolean

Alias
UMLS CUI [1]
C0006147
second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Description

Second Primary Cancer

Data type

boolean

Alias
UMLS CUI [1]
C0751623
inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
Description

Aspirin Unable to discontinue Period | Non-Steroidal Anti-Inflammatory Agents Unable to discontinue Period

Data type

boolean

Alias
UMLS CUI [1,1]
C0004057
UMLS CUI [1,2]
C1548265
UMLS CUI [1,3]
C1948053
UMLS CUI [2,1]
C0003211
UMLS CUI [2,2]
C1548265
UMLS CUI [2,3]
C1948053
inability or unwillingness to take folic acid or vitamin b12 supplementation.
Description

Folate intake Unwilling | Vitamin B12 supplement Intake Unwilling

Data type

boolean

Alias
UMLS CUI [1,1]
C0564428
UMLS CUI [1,2]
C0558080
UMLS CUI [2,1]
C3661610
UMLS CUI [2,2]
C1512806
UMLS CUI [2,3]
C0558080
Back to the top of the page

Similar models

Eligibility Non-Small Cell Lung Cancer NCT00078260

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | Disease Curative treatment Amenable | TNM clinical staging
Item
diagnosis of locally advanced or metastatic (stage iii or iv at entry) non-small cell lung cancer (nsclc) that is not amenable to curative therapy.
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C0278987 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C3900053 (UMLS CUI [3,3])
C3258246 (UMLS CUI [4])
Prior Chemotherapy Platinum-Based Locally Advanced Malignant Neoplasm | Prior Chemotherapy Platinum-Based Metastatic Neoplasm | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Chemotherapy Additional Recurrence
Item
patients must have been previously treated with one platinum-containing chemotherapy regimen for locally advanced or metastatic disease. patients are also eligible if they have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant chemotherapy, but must have received an additional chemotherapy regimen upon recurrence.
boolean
C1514457 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C0677984 (UMLS CUI [1,3])
C1514457 (UMLS CUI [2,1])
C1514162 (UMLS CUI [2,2])
C2939420 (UMLS CUI [2,3])
C0600558 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C0085533 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C1524062 (UMLS CUI [5,2])
C2825055 (UMLS CUI [5,3])
cancer treatment Systemic Quantity
Item
no more than two prior systemic anti-cancer therapies will be allowed.
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
prior radiation therapy Bone Marrow Percentage | prior radiation therapy Whole-Pelvis | prior radiation therapy Completed | Toxic effect Patient Recovered
Item
prior radiation therapy is allowed to less than 25% of the bone marrow. prior radiation to the whole pelvis is not allowed. prior radiotherapy must be completed at least 2 weeks before study enrollment, and the patient must have recovered from the acute toxic effects of the treatment prior to study enrollment.
boolean
C0279134 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C3827467 (UMLS CUI [2,2])
C0279134 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C0030705 (UMLS CUI [4,2])
C0521108 (UMLS CUI [4,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy
Item
pregnancy.
boolean
C0032961 (UMLS CUI [1])
Breast Feeding
Item
breast-feeding.
boolean
C0006147 (UMLS CUI [1])
Second Primary Cancer
Item
second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
boolean
C0751623 (UMLS CUI [1])
Aspirin Unable to discontinue Period | Non-Steroidal Anti-Inflammatory Agents Unable to discontinue Period
Item
inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a 5-day period.
boolean
C0004057 (UMLS CUI [1,1])
C1548265 (UMLS CUI [1,2])
C1948053 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2,1])
C1548265 (UMLS CUI [2,2])
C1948053 (UMLS CUI [2,3])
Folate intake Unwilling | Vitamin B12 supplement Intake Unwilling
Item
inability or unwillingness to take folic acid or vitamin b12 supplementation.
boolean
C0564428 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C3661610 (UMLS CUI [2,1])
C1512806 (UMLS CUI [2,2])
C0558080 (UMLS CUI [2,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial